Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3

J Card Fail. 2023 Nov;29(11):1576-1582. doi: 10.1016/j.cardfail.2023.07.003. Epub 2023 Jul 18.
No abstract available

Keywords: Aficamten; REDWOOD-HCM; obstructive hypertrophic cardiomyopathy; refractory obstructive hypertrophic cardiomyopathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Arrhythmia Agents
  • Cardiomyopathy, Hypertrophic* / drug therapy
  • Disopyramide / adverse effects
  • Heart Failure* / drug therapy
  • Humans
  • Sequoia*

Substances

  • Disopyramide
  • Anti-Arrhythmia Agents